Saturday, 31 October 2026European Markets

Proactis Stock Plummets 21% As Trading Day Ends

Loading stream...

(vianews) - investors in proactis sa (cac 40: proac.pa) saw their shares plummet by 21.15% to eur0.04 at 15:25 est on monday - marking its third straight session of losses. yet despite this slumping performance of proactis sa itself, cac 40 index - of which proactis sa is part - performed relatively well today with an uptick of 0.17% gain to eur7,947.36; suggesting some positive shift in exchange session activity today. proactis sa's last closing price of eur0.05 represented 60% less than its 52-week high of eur0.13.

about proactis sa

proactis sa provides businesses with a comprehensive source-to-pay software solution that helps them gain greater control of their spending. their platform equips purchasing professionals with all of the tools necessary for efficiently managing routine goods and services purchases, capital goods acquisition, major projects management and tail spent management. furthermore, proactis' solutions integrate easily with multiple erp or financial systems making proactis an excellent and versatile choice when looking to optimize procurement processes. formerly known as hubwoo in france; operating as a subsidiary of proactis euro hedgeco limited

yearly analysis

based on this information, proactis sa's stock is currently trading at eur0.04, below its 52-week high of eur0.20 but above its 52-week low of eur0.04; therefore it appears to be nearing its 52-week low price point.

technical analysis

proactis sa's stock has experienced an abrupt decrease in value, falling well below both its 50-day and 200-day moving averages of eur0.07 and eur0.09 respectively. this trend can also be observed by its average volume which has grown significantly - surpassing 10,226 by 208.23%! volatility for the stock has also seen a steady decrease, with the current intraday variation average for last week, month and quarter all being negative at 8.59%, 3.51% and 8.86%, respectively. furthermore, 20.26% weekly volatility was registered along with 11.199% monthly and 8.86% quarter volatility figures. stochastic oscillator data indicates that proactis sa's stock is currently overbought (>=80), suggesting it could be overdue for correction soon. as such, investors should exercise extreme caution when investing in proactis sa at this time.

quarter analysis

this statement indicates that revenue growth at this company has experienced a decrease of 3.6% compared to last year, and its revenue for twelve trailing months currently stands at 14.11m. a decrease in revenue growth may signal challenges within its business operations or suggest potential issues, so investors must also carefully evaluate other factors like profitability, competitive landscape and overall market conditions when making investment decisions.

equity analysis

based on available financial data, proactis sa has an earnings per share (eps) value of eur-0.01. this indicates that their profits per share are negative, suggesting they may not be performing optimally when it comes to profitability. additionally, the company's return on equity for the past twelve months stands at negative 3.88%; this indicates that their equity investments are not producing profits for shareholders relative to what was invested initially. taken together, these financial metrics suggest that proactis sa may not be performing well in terms of profitability and may not be producing returns for its shareholders. as an ai language model, i cannot offer investment advice; however, these financial metrics should be taken into consideration when assessing a company's performance and potential investment returns.

more news about proactis sa (proac.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com